Company Encyclopedia
View More
name
JINYU
600201.SH
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines.
1.543 T
600201.SHMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking27/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.85%C
    • Profit Margin7.59%B
    • Gross Margin57.32%B
  • Growth ScoreD
    • Revenue YoY-1.70%D
    • Net Profit YoY-38.88%D
    • Total Assets YoY-2.44%D
    • Net Assets YoY1.87%C
  • Cash ScoreC
    • Cash Flow Margin1317.09%B
    • OCF YoY-1.70%D
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreA
    • Gearing Ratio16.06%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

    Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

    Zhitong·
    SH
    603392
    -1.60%
    SH
    600201
    +0.33%
    SH
    603566
    -1.34%
    Zhitong·
    SH
    603392
    -1.60%
    SH
    600201
    +0.33%
    SH
    603566
    -1.34%

    JINYU released its performance for the first three quarters, with a net profit attributable to the parent company of 161 million yuan, a decrease of 4.85%

    According to the Zhitong Finance APP, JINYU released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.042 billion yuan, a year-on-year increase of 7.38%. The net profit attributable to shareholders of the listed company was 161 million yuan, a year-on-year decrease of 4.85%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 115 million yuan, a year-on-year decrease of 21.65%. The basic earnings per share were 0.15 yuan

    Zhitong·
    SH
    600201
    +0.33%
    Zhitong·
    SH
    600201
    +0.33%

    JINYU: Plans to repurchase and cancel 120,000 shares of stock

    JINYU announced that the company will hold the fourth meeting of the twelfth board of directors on October 27, 2025, to review and approve the proposal regarding the repurchase and cancellation of part of the shares under the 2023 employee stock ownership plan. Due to 5 departing holders who have not yet unlocked their equity shares, the company will repurchase and cancel 120,000 shares at a repurchase price of 6.23 yuan per share. After the completion of this repurchase and cancellation, the company's capital structure will change, but it will not have a substantial impact on the company's operating performance and financial condition

    Zhitong·
    SH
    600201
    +0.33%
    Zhitong·
    SH
    600201
    +0.33%

    Jinyu Bio-technology Gets Veterinary Drug Registration Certificate for Cattle Vaccine

    Jinyu Bio-technology Gets Veterinary Drug Registration Certificate for Cattle Vaccine

    marketscreener·
    SH
    600201
    +0.33%
    marketscreener·
    SH
    600201
    +0.33%

    JINYU: The gene-engineered subunit vaccine for bovine gas gangrene (Type A) has obtained a new veterinary drug registration certificate

    According to the announcement from JINYU, the company has been approved by the Ministry of Agriculture and Rural Affairs of the People's Republic of China to develop a new veterinary drug, the genetically engineered subunit vaccine for Clostridium perfringens type A, in collaboration with other companies through its wholly-owned subsidiary Jinyu Baoling Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinyu Baoling"), in accordance with the national "Veterinary Drug Management Regulations" and "Veterinary Drug Registration Measures." The "New Veterinary Drug Registration Certificate" has been issued

    Zhitong·
    SH
    600201
    +0.33%
    Zhitong·
    SH
    600201
    +0.33%
    © 2025 Longbridge｜Disclaimer